Select a company

Go

Company Stage

  • Private (seed)
  • Private (post-seed)
  • Quoted

Sector

  • Energy and Renewables
  • IT & Communications
  • Chemicals & Materials
  • Biotech
  • Healthcare

University

  • University of Bath
  • University of Bristol
  • University of Cardiff
  • University of Glasgow
  • University of Leeds
  • King's College London
  • Queen Mary, University of London
  • University of Manchester
  • University of Nottingham
  • University of Oxford
  • University of Sheffield
  • University of Southampton
  • University of Surrey
  • Swansea University
  • University of York
  • Other

Stakeholder

  • IP Group
  • IP Venture Fund
  • Top 10 Holdings
    by value
Pharma & Biotech

University: Cardiff (Fusion IP)

Company Stage: Private (seed)

Progenteq is developing a novel cartiledge replacement therapy that has the potential to revolutionise the treatment of acute knee injuries. The company was founded in 2010 on the work of Professor Charlie Archer's research group at Cardiff University's School of Biosciences. Professor Archer is Leader of the Connective Tissue Biology Group, recognised for excellence in tissue engineering and repair research.

As at 31 Dec 2012

IP Group holding

 

12.0%

Holding represents undiluted beneficial equity interest excluding debt

Related news

There is currently no news available.

More portfolio news